Search
Onconetix Inc
ONCOAdd to Watchlist
0.956USD
-0.124-11.53%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
263.25KMarket Cap
0.00P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-11.53%
5 Days
-2.15%
1 Month
-8.13%
6 Months
-88.13%
Year to Date
-87.75%
1 Year
-95.89%
Key Figures
1.100Open
1.100High
397.51KVolume
0.00P/E TTM
--P/E Dynamic
--Dividend TTM
144.28%Turnover Ratio
1.080Prev. Close
0.930Low
325.20KTurnover
LossP/E Static
0.02P/B
0.00%Div Yield TTM
-57.73%ROA
382.50052wk High
1.61Volume Ratio
-58.90MNet Profit
275.52KShares
1376.5865EPS TTM
2.78Beta
-127.45%ROE
0.91152wk Low
15.74%Amplitude
-7.71%Gross Margin
263.25KMarket Cap
0.41Reward/Risk
9.45%Risk Rate
TradingKey Stock Score of Onconetix Inc
Currency: USD Updated: 2026-07-02Key Insights
Onconetix Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 132 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Onconetix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Onconetix Inc Highlights
StrengthsRisks
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1294.63% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 815.37K.
Overvalued
The company’s latest PE is 0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 26.70K shares, increasing 7.56% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.94.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Onconetix Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Onconetix Inc Info
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Ticker SymbolONCO
CompanyOnconetix Inc
CEOFedasz (Karina M)
Websitehttps://www.onconetix.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Onconetix Inc (ONCO)?
The current price of Onconetix Inc (ONCO) is 0.96.
What is the symbol of Onconetix Inc?
The ticker symbol of Onconetix Inc is ONCO.
What is the 52-week high of Onconetix Inc?
The 52-week high of Onconetix Inc is 382.50.
What is the 52-week low of Onconetix Inc?
The 52-week low of Onconetix Inc is 0.91.
What is the market capitalization of Onconetix Inc?
The market capitalization of Onconetix Inc is 263.25K.
What is the Earnings Per Share (EPS TTM) of Onconetix Inc (ONCO)?
The Earnings Per Share (EPS TTM) of Onconetix Inc (ONCO) is -828.15.